XML 87 R71.htm IDEA: XBRL DOCUMENT
v3.10.0.1

COMMITMENTS AND CONTINGENCIES (Details 2) - USD ($) $ in Millions | Mar. 21, 2007 | Dec. 31, 2018
--- | --- | ---
SkyePharma Holding, Inc. |  |
Commitments |  |
Total milestone payments paid |  | $ 36.0
SkyePharma Holding, Inc. | Maximum |  |
Commitments |  |
Milestone payments for EXPAREL agreed in connection with acquisition |  | $ 62.0
PPI-California |  |
Commitments |  |
Initial purchase price for acquisition | $ 19.6 |

X
- Definition Represents the milestone payments agreed to be paid by the entity for the sale of the product, in connection with the acquisition. + References No definition available. + Details
Name: | pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition
Namespace Prefix: | pcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Total Milestone Payments Yet to be Paid for Sale of Product in Connection with Acquisition + References No definition available. + Details
Name: | pcrx_TotalMilestonePaymentsYettobePaidforSaleofProductinConnectionwithAcquisition
Namespace Prefix: | pcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionContingentConsiderationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=pcrx_SkyePharmaHoldingIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=pcrx_CaliforniaOperatingSubsidiaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |